Skip to main content
Top
Published in: Journal of Translational Medicine 1/2022

01-12-2022 | Albuminuria | Research

Prediction of 3-year risk of diabetic kidney disease using machine learning based on electronic medical records

Authors: Zheyi Dong, Qian Wang, Yujing Ke, Weiguang Zhang, Quan Hong, Chao Liu, Xiaomin Liu, Jian Yang, Yue Xi, Jinlong Shi, Li Zhang, Ying Zheng, Qiang Lv, Yong Wang, Jie Wu, Xuefeng Sun, Guangyan Cai, Shen Qiao, Chengliang Yin, Shibin Su, Xiangmei Chen

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Background

Established prediction models of Diabetic kidney disease (DKD) are limited to the analysis of clinical research data or general population data and do not consider hospital visits. Construct a 3-year diabetic kidney disease risk prediction model in patients with type 2 diabetes mellitus (T2DM) using machine learning, based on electronic medical records (EMR).

Methods

Data from 816 patients (585 males) with T2DM and 3 years of follow-up at the PLA General Hospital. 46 medical characteristics that are readily available from EMR were used to develop prediction models based on seven machine learning algorithms (light gradient boosting machine [LightGBM], eXtreme gradient boosting, adaptive boosting, artificial neural network, decision tree, support vector machine, logistic regression). Model performance was evaluated using the area under the receiver operating characteristic curve (AUC). Shapley additive explanation (SHAP) was used to interpret the results of the best performing model.

Results

The LightGBM model had the highest AUC (0.815, 95% CI 0.747–0.882). Recursive feature elimination with random forest and SHAP plot based on LightGBM showed that older patients with T2DM with high homocysteine (Hcy), poor glycemic control, low serum albumin (ALB), low estimated glomerular filtration rate (eGFR), and high bicarbonate had an increased risk of developing DKD over the next 3 years.

Conclusions

This study constructed a 3-year DKD risk prediction model in patients with T2DM and normo-albuminuria using machine learning and EMR. The LightGBM model is a tool with potential to facilitate population management strategies for T2DM care in the EMR era.
Literature
2.
go back to reference Sardu C, Gargiulo G, Esposito G, Paolisso G, Marfella R. Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19. Cardiovasc Diabetol. 2020;19:76.PubMedPubMedCentralCrossRef Sardu C, Gargiulo G, Esposito G, Paolisso G, Marfella R. Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19. Cardiovasc Diabetol. 2020;19:76.PubMedPubMedCentralCrossRef
3.
go back to reference Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:1985.CrossRef Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:1985.CrossRef
4.
go back to reference Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290:3101–14.PubMedCrossRef Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290:3101–14.PubMedCrossRef
5.
go back to reference Makino M, Yoshimoto R, Ono M, Itoko T, Katsuki T, Koseki A, et al. Artificial intelligence predicts the progression of diabetic kidney disease using big data machine learning. Sci Rep. 2019;9:11862.PubMedPubMedCentralCrossRef Makino M, Yoshimoto R, Ono M, Itoko T, Katsuki T, Koseki A, et al. Artificial intelligence predicts the progression of diabetic kidney disease using big data machine learning. Sci Rep. 2019;9:11862.PubMedPubMedCentralCrossRef
6.
go back to reference Weber C, Röschke L, Modersohn L, Lohr C, Kolditz T, Hahn U, et al. Optimized Identification of Advanced Chronic Kidney Disease and Absence of Kidney Disease by Combining Different Electronic Health Data Resources and by Applying Machine Learning Strategies. J Clin Med. 2020;9:89. Weber C, Röschke L, Modersohn L, Lohr C, Kolditz T, Hahn U, et al. Optimized Identification of Advanced Chronic Kidney Disease and Absence of Kidney Disease by Combining Different Electronic Health Data Resources and by Applying Machine Learning Strategies. J Clin Med. 2020;9:89.
7.
go back to reference Sun L, Shang J, Xiao J, Zhao Z. Development and validation of a predictive model for end-stage renal disease risk in patients with diabetic nephropathy confirmed by renal biopsy. PeerJ. 2020;8:e8499.PubMedPubMedCentralCrossRef Sun L, Shang J, Xiao J, Zhao Z. Development and validation of a predictive model for end-stage renal disease risk in patients with diabetic nephropathy confirmed by renal biopsy. PeerJ. 2020;8:e8499.PubMedPubMedCentralCrossRef
8.
go back to reference Ramspek CL, Evans M, Wanner C. Kidney Failure Prediction Models: A Comprehensive External Validation Study in Patients with Advanced CKD. J Am Soc Nephrol. 2021;32:1174–86.PubMedCrossRef Ramspek CL, Evans M, Wanner C. Kidney Failure Prediction Models: A Comprehensive External Validation Study in Patients with Advanced CKD. J Am Soc Nephrol. 2021;32:1174–86.PubMedCrossRef
9.
go back to reference Ravizza S, Huschto T, Adamov A, Böhm L, Büsser A, Flöther FF, et al. Predicting the early risk of chronic kidney disease in patients with diabetes using real-world data. Nat Med. 2019;25:57–9.PubMedCrossRef Ravizza S, Huschto T, Adamov A, Böhm L, Büsser A, Flöther FF, et al. Predicting the early risk of chronic kidney disease in patients with diabetes using real-world data. Nat Med. 2019;25:57–9.PubMedCrossRef
10.
go back to reference Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
11.
go back to reference Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.PubMedPubMedCentralCrossRef Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.PubMedPubMedCentralCrossRef
12.
go back to reference Lemaître G, Nogueira F, Aridas CK. Imbalanced-learn: A python toolbox to tackle the curse of imbalanced datasets in machine learning. J Mach Learn Res. 2017;18:559–63. Lemaître G, Nogueira F, Aridas CK. Imbalanced-learn: A python toolbox to tackle the curse of imbalanced datasets in machine learning. J Mach Learn Res. 2017;18:559–63.
13.
go back to reference Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: Machine learning in Python. J Mach Learn Res. 2011;12:2825–30. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: Machine learning in Python. J Mach Learn Res. 2011;12:2825–30.
15.
go back to reference Ke G, Meng Q, Finley T, Wang T, Chen W, Ma W, et al. Lightgbm: A highly efficient gradient boosting decision tree. Adv Neural Inf Process Syst. 2017;30:3146–54. Ke G, Meng Q, Finley T, Wang T, Chen W, Ma W, et al. Lightgbm: A highly efficient gradient boosting decision tree. Adv Neural Inf Process Syst. 2017;30:3146–54.
16.
go back to reference Chen T, Guestrin C: Xgboost: A scalable tree boosting system. In: Proceedings of the 22nd acm sigkdd international conference on knowledge discovery and data mining: 2016. p. 785–94. Chen T, Guestrin C: Xgboost: A scalable tree boosting system. In: Proceedings of the 22nd acm sigkdd international conference on knowledge discovery and data mining: 2016. p. 785–94.
17.
go back to reference Freund Y, Schapire R, Abe N. A short introduction to boosting. Journal-Japanese Society For Artificial Intelligence. 1999;14:1612. Freund Y, Schapire R, Abe N. A short introduction to boosting. Journal-Japanese Society For Artificial Intelligence. 1999;14:1612.
19.
go back to reference Hastie T, Tibshirani R, Friedman J. The elements of statistical learning: data mining, inference, and prediction. New York: Springer. 2009. Hastie T, Tibshirani R, Friedman J. The elements of statistical learning: data mining, inference, and prediction. New York: Springer. 2009.
20.
go back to reference Cortes C, Vapnik V. Support-vector networks Machine learning. 1995;20:273–97. Cortes C, Vapnik V. Support-vector networks Machine learning. 1995;20:273–97.
21.
go back to reference Fitzmaurice G, Laird N. Multivariate analysis: Discrete variables (logistic regression). 2001. Fitzmaurice G, Laird N. Multivariate analysis: Discrete variables (logistic regression). 2001.
22.
go back to reference Handelman G, Kok H, Chandra R, Razavi A, Lee M, Asadi H. eD octor: machine learning and the future of medicine. J Intern Med. 2018;284:603–19.PubMedCrossRef Handelman G, Kok H, Chandra R, Razavi A, Lee M, Asadi H. eD octor: machine learning and the future of medicine. J Intern Med. 2018;284:603–19.PubMedCrossRef
23.
go back to reference Tseng PY, Chen YT, Wang CH, Chiu KM, Peng YS, Hsu SP, et al. Prediction of the development of acute kidney injury following cardiac surgery by machine learning. Crit Care. 2020;24:478.PubMedPubMedCentralCrossRef Tseng PY, Chen YT, Wang CH, Chiu KM, Peng YS, Hsu SP, et al. Prediction of the development of acute kidney injury following cardiac surgery by machine learning. Crit Care. 2020;24:478.PubMedPubMedCentralCrossRef
24.
go back to reference Lundberg SM, Lee S-I. A unified approach to interpreting model predictions. Adv Neural Inf Process Syst. 2017;30:346. Lundberg SM, Lee S-I. A unified approach to interpreting model predictions. Adv Neural Inf Process Syst. 2017;30:346.
25.
go back to reference Guyon I, Weston J, Barnhill S, Vapnik V. Gene selection for cancer classification using support vector machines. Mach Learn. 2002;46:389–422.CrossRef Guyon I, Weston J, Barnhill S, Vapnik V. Gene selection for cancer classification using support vector machines. Mach Learn. 2002;46:389–422.CrossRef
26.
go back to reference Lundberg SM, Lee S-I. A unified approach to interpreting model predictions. In: Proceedings of the 31st international conference on neural information processing systems: 2017. p. 4768–77. Lundberg SM, Lee S-I. A unified approach to interpreting model predictions. In: Proceedings of the 31st international conference on neural information processing systems: 2017. p. 4768–77.
27.
go back to reference Dong ZY. Data from: supplementary materials for JCEM. OSF. Deposited October 10, 2021. Dong ZY. Data from: supplementary materials for JCEM. OSF. Deposited October 10, 2021.
28.
go back to reference Zhao Y, Wang T, Bove R, Cree B, Henry R, Lokhande H, et al. Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study. NPJ Digit Med. 2020;3:135.PubMedPubMedCentralCrossRef Zhao Y, Wang T, Bove R, Cree B, Henry R, Lokhande H, et al. Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study. NPJ Digit Med. 2020;3:135.PubMedPubMedCentralCrossRef
30.
go back to reference Zhu Y, Cai X, Liu Y, Hu M, Zhou L, Liu W, et al. Serum Albumin, but not Bilirubin, is Associated with Diabetic Chronic Vascular Complications in a Chinese Type 2 Diabetic Population. Sci Rep. 2019;9:12086.PubMedPubMedCentralCrossRef Zhu Y, Cai X, Liu Y, Hu M, Zhou L, Liu W, et al. Serum Albumin, but not Bilirubin, is Associated with Diabetic Chronic Vascular Complications in a Chinese Type 2 Diabetic Population. Sci Rep. 2019;9:12086.PubMedPubMedCentralCrossRef
31.
go back to reference Damotte V, Lizée A, Tremblay M, Agrawal A, Khankhanian P, Santaniello A, et al. Harnessing electronic medical records to advance research on multiple sclerosis. Mult Scler. 2019;25:408–18.PubMedCrossRef Damotte V, Lizée A, Tremblay M, Agrawal A, Khankhanian P, Santaniello A, et al. Harnessing electronic medical records to advance research on multiple sclerosis. Mult Scler. 2019;25:408–18.PubMedCrossRef
32.
go back to reference Cheung M, Cobb AN, Kuo PC. Predicting burn patient mortality with electronic medical records. Surgery. 2018;164:839–47.PubMedCrossRef Cheung M, Cobb AN, Kuo PC. Predicting burn patient mortality with electronic medical records. Surgery. 2018;164:839–47.PubMedCrossRef
34.
go back to reference Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017;390:1888–917.PubMedCrossRef Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017;390:1888–917.PubMedCrossRef
35.
go back to reference Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375:323–34.PubMedCrossRef Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375:323–34.PubMedCrossRef
36.
go back to reference Fioretto P, Dodson PM, Ziegler D, Rosenson RS. Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol. 2010;6:19–25.PubMedCrossRef Fioretto P, Dodson PM, Ziegler D, Rosenson RS. Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol. 2010;6:19–25.PubMedCrossRef
37.
go back to reference Rodriguez-Romero V, Bergstrom RF, Decker BS, Lahu G, Vakilynejad M, Bies RR. Prediction of Nephropathy in Type 2 Diabetes: An Analysis of the ACCORD Trial Applying Machine Learning Techniques. Clin Transl Sci. 2019;12:519–28.PubMedPubMedCentralCrossRef Rodriguez-Romero V, Bergstrom RF, Decker BS, Lahu G, Vakilynejad M, Bies RR. Prediction of Nephropathy in Type 2 Diabetes: An Analysis of the ACCORD Trial Applying Machine Learning Techniques. Clin Transl Sci. 2019;12:519–28.PubMedPubMedCentralCrossRef
38.
go back to reference Elley CR, Robinson T, Moyes SA, Kenealy T, Collins J, Robinson E, et al. Derivation and validation of a renal risk score for people with type 2 diabetes. Diabetes Care. 2013;36:3113–20.PubMedPubMedCentralCrossRef Elley CR, Robinson T, Moyes SA, Kenealy T, Collins J, Robinson E, et al. Derivation and validation of a renal risk score for people with type 2 diabetes. Diabetes Care. 2013;36:3113–20.PubMedPubMedCentralCrossRef
39.
go back to reference Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V, et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol. 2012;7:401–8.PubMedCrossRef Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V, et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol. 2012;7:401–8.PubMedCrossRef
40.
go back to reference Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis. 2014;63:S39-62.PubMedCrossRef Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis. 2014;63:S39-62.PubMedCrossRef
41.
go back to reference Silveiro SP, Friedman R, de Azevedo MJ, Canani LH, Gross JL. Five-year prospective study of glomerular filtration rate and albumin excretion rate in normofiltering and hyperfiltering normoalbuminuric NIDDM patients. Diabetes Care. 1996;19:171–4.PubMedCrossRef Silveiro SP, Friedman R, de Azevedo MJ, Canani LH, Gross JL. Five-year prospective study of glomerular filtration rate and albumin excretion rate in normofiltering and hyperfiltering normoalbuminuric NIDDM patients. Diabetes Care. 1996;19:171–4.PubMedCrossRef
42.
go back to reference Thomson HJ, Ekinci EI, Radcliffe NJ, Seah JM, MacIsaac RJ, Jerums G, et al. Elevated baseline glomerular filtration rate (GFR) is independently associated with a more rapid decline in renal function of patients with type 1 diabetes. J Diabetes Complications. 2016;30:256–61.PubMedCrossRef Thomson HJ, Ekinci EI, Radcliffe NJ, Seah JM, MacIsaac RJ, Jerums G, et al. Elevated baseline glomerular filtration rate (GFR) is independently associated with a more rapid decline in renal function of patients with type 1 diabetes. J Diabetes Complications. 2016;30:256–61.PubMedCrossRef
43.
go back to reference Tonneijck L, Muskiet MH, Smits MM, van Bommel EJ, Heerspink HJ, van Raalte DH, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017;28:1023–39.PubMedPubMedCentralCrossRef Tonneijck L, Muskiet MH, Smits MM, van Bommel EJ, Heerspink HJ, van Raalte DH, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017;28:1023–39.PubMedPubMedCentralCrossRef
44.
go back to reference Thomas MC, Rosengård-Bärlund M, Mills V, Rönnback M, Thomas S, Forsblom C, et al. Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care. 2006;29:317–22.PubMedCrossRef Thomas MC, Rosengård-Bärlund M, Mills V, Rönnback M, Thomas S, Forsblom C, et al. Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care. 2006;29:317–22.PubMedCrossRef
45.
go back to reference Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes Metab. 2000;26:254–64.PubMed Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes Metab. 2000;26:254–64.PubMed
46.
go back to reference Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.PubMedCrossRef Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.PubMedCrossRef
47.
go back to reference Alla VM, Agrawal V, DeNazareth A, Mohiuddin S, Ravilla S, Rendell M. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs. Drugs. 2013;73:1025–54.PubMedCrossRef Alla VM, Agrawal V, DeNazareth A, Mohiuddin S, Ravilla S, Rendell M. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs. Drugs. 2013;73:1025–54.PubMedCrossRef
48.
go back to reference Ma L, Liu Q, Jiang Y, Zhao H, Zhao T, Cao Y, et al. Genetically elevated circulating homocysteine concentrations increase the risk of diabetic kidney disease in Chinese diabetic patients. J Cell Mol Med. 2019;23:2794–800.PubMedPubMedCentralCrossRef Ma L, Liu Q, Jiang Y, Zhao H, Zhao T, Cao Y, et al. Genetically elevated circulating homocysteine concentrations increase the risk of diabetic kidney disease in Chinese diabetic patients. J Cell Mol Med. 2019;23:2794–800.PubMedPubMedCentralCrossRef
49.
go back to reference Schutte E, Lambers Heerspink HJ, Lutgers HL, Bakker SJ, Vart P, Wolffenbuttel BH, et al. SeruM BICARBONATE AND KIDNEY DISEASE PROGRESSION AND CARDIOVASCULAR OUTCOME IN PATIENTS WITH DIABETIC NEPHROPATHY: A POST HOC ANALysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial). Am J Kidney Dis. 2015;66:450–8.PubMedCrossRef Schutte E, Lambers Heerspink HJ, Lutgers HL, Bakker SJ, Vart P, Wolffenbuttel BH, et al. SeruM BICARBONATE AND KIDNEY DISEASE PROGRESSION AND CARDIOVASCULAR OUTCOME IN PATIENTS WITH DIABETIC NEPHROPATHY: A POST HOC ANALysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial). Am J Kidney Dis. 2015;66:450–8.PubMedCrossRef
50.
go back to reference Caravaca F, Arrobas M, Pizarro JL, Espárrago JF. Metabolic acidosis in advanced renal failure: differences between diabetic and nondiabetic patients. Am J Kidney Dis. 1999;33:892–8.PubMedCrossRef Caravaca F, Arrobas M, Pizarro JL, Espárrago JF. Metabolic acidosis in advanced renal failure: differences between diabetic and nondiabetic patients. Am J Kidney Dis. 1999;33:892–8.PubMedCrossRef
51.
go back to reference Hood VL, Danforth E Jr, Horton ES, Tannen RL. Impact of hydrogen ion on fasting ketogenesis: feedback regulation of acid production. Am J Physiol. 1982;242:F238–45.PubMed Hood VL, Danforth E Jr, Horton ES, Tannen RL. Impact of hydrogen ion on fasting ketogenesis: feedback regulation of acid production. Am J Physiol. 1982;242:F238–45.PubMed
52.
go back to reference Gurudas S, Nugawela M, Prevost AT, Sathish T, Mathur R, Rafferty JM, et al. Development and validation of resource-driven risk prediction models for incident chronic kidney disease in type 2 diabetes. Sci Rep. 2021;11:13654.PubMedPubMedCentralCrossRef Gurudas S, Nugawela M, Prevost AT, Sathish T, Mathur R, Rafferty JM, et al. Development and validation of resource-driven risk prediction models for incident chronic kidney disease in type 2 diabetes. Sci Rep. 2021;11:13654.PubMedPubMedCentralCrossRef
Metadata
Title
Prediction of 3-year risk of diabetic kidney disease using machine learning based on electronic medical records
Authors
Zheyi Dong
Qian Wang
Yujing Ke
Weiguang Zhang
Quan Hong
Chao Liu
Xiaomin Liu
Jian Yang
Yue Xi
Jinlong Shi
Li Zhang
Ying Zheng
Qiang Lv
Yong Wang
Jie Wu
Xuefeng Sun
Guangyan Cai
Shen Qiao
Chengliang Yin
Shibin Su
Xiangmei Chen
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03339-1

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.